Immupharma Share Price (IMM)

Share Name	Share Symbol	Market	Type	Share ISIN	Share Description
Immupharma Plc	LSE:IMM	London	Ordinary Share	GB0033711010	ORD 10P

	Price Change	% Change	Share Price	Shares Traded	Last Trade
	-0.57p	-5.34%	10.10p	1,348,336	16:35:22

Bid Price		Offer Price	High Price	Low Price	Open Price
10.00p		10.20p	10.32p	9.91p	10.32p

Industry Sector	Turnover (m)	Profit (m)	EPS - Basic	PE Ratio	Market Cap (m)
Pharmaceuticals & Biotechnology	0.15	-7.00	-4.75		14.1

Related Shares
Astrazeneca (AZN), Glaxosmithkline (GSK), Valirx (VAL), Venn Life Sciences (VENN)

Immupharma (IMM) Latest News

Immupharma News

Date	Time	Source	Headline
07/5/2019	11:06	ALNC	ImmuPharma Exploring European Listing For Combined French Businesses..
07/5/2019	08:15	UKREG	Immupharma PLC Corporate Update - Replacement
01/4/2019	14:07	ALNC	ImmuPharma Loses Exclusivity Period For Talks With Incanthera
01/4/2019	07:00	UKREG	Immupharma PLC Update on Nucant Cancer Programme
14/3/2019	10:41	ALNC	ImmuPharma Preparing For Lupuzor Drug Managed Access Programme
26/2/2019	07:02	RNSNON	Immupharma PLC Technology review published-Nature Communications
31/12/2018	09:19	ALNC	ImmuPharma Expects Nucant Cancer Agreement To Completed In 2019
31/12/2018	07:00	UKREG	Immupharma PLC Clinical Development Collaboration with Incanthera
17/12/2018	07:01	UKREG	Immupharma PLC Appointment of Nominated Adviser
07/12/2018	11:26	ALNC	ImmuPharma Progressing To Make Lupuzor Available To Patients

More Immupharma News

Immupharma Takeover Rumours

Immupharma (IMM) Share Charts

1 Year Immupharma Chart

1 Month Immupharma Chart

Intraday Immupharma Chart

Immupharma (IMM) Discussions and Chat

Immupharma Forums and Chat

Date	Time	Title	Posts
22/5/2019	12:36	IMMUPHARMA - IN FINAL PHASE 3 LUPUS TRIAL TARGETING BLOCKBUSTER ($1bn+) REVENUES	34,128
07/5/2019	12:05	(IMM) ImmuPharma PLC boss excited by “blockbuster potential” of Lupuzor	14
03/4/2019	08:58	Sell order	13
16/8/2018	11:44	ImmuPharma interview	2
30/4/2018	09:55	ImmuPharma - Global Potential Blockbusters & Huge Potential Upside	103

Add a New Thread

Immupharma (IMM) Most Recent Trades

Trade Time	Trade Price	Trade Size	Trade Value	Trade Type
16:05:44	10.10	290,000	29,290.00	O
15:29:24	10.00	2,255	225.50	AT
15:19:49	10.20	2,393	244.09	AT
15:13:41	10.10	784	79.18	O
15:04:49	10.17	10,000	1,017.12	O

View all Immupharma trades in real-time

Immupharma (IMM) Top Chat Posts

Date	Subject
22/5/2019 09:20	Immupharma Daily Update: Immupharma Plc is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker IMM. The last closing price for Immupharma was 10.67p. Immupharma Plc has a 4 week average price of 8.50p and a 12 week average price of 8.50p. The 1 year high share price is 37p while the 1 year low share price is currently 8.50p. There are currently 139,467,430 shares in issue and the average daily traded volume is 815,114 shares. The market capitalisation of Immupharma Plc is £14,086,210.43. Read Full Thread Reply
07/5/2019 08:28	borromini1: RNS 1934Y Doesn’t provide the level of detail to change the current share price. IMM have not explicitly stated that regulatory authorities have given approvel for the MAP to proceed, while using the establishment of a pre-agreed final route to market scenario as the reason for suspension of the MAP process. The Open Label Extension still offers up no indication of the outcome, but surely the results can’t be delayed beyond the end of June or after the AGM. Rearranging the assets for sale on a European market is trying another tack after the Incanthera failure. The Final Results for 2018 due this month will presumably confirm that £2m of IMM funds are now locked into Incanthera. Tim’s role as chairman and fund raiser now seems diminished. Read Full Thread Follow Reply
29/11/2018 13:14	sicilian_kan: Well the share price is looking perky. In my view there are three possible reasons: 1. Shareholder anticipation of a Ureka deal. NASH is a hot pharma area at the moment. It was announced yesterday that Genentech bought Jecure Therapeutics. See the very interesting article below about the Pharma race to acquire NASH hTTp://www.pmlive.com/pharma_news/roche_enters_nash_race_with_deal_to_buy_jecure_1266324 "Roche has joined the melee of pharma companies trying to claim a share of the market for non-alcoholic steatohepatitis (NASH) drugs, cutting a deal to acquire US start-up Jecure Therapeutics." "NASH is a hot topic in pharma development at the moment, with a host of companies vying to bring forward new treatments for the disease, which is viewed as an emerging health crisis - and an untapped pharma market." "Some predictions put the market potential at $20bn to $35bn a year." Now we know from the Interims that: "Ureka, ImmuPharma's wholly owned subsidiary, based in Bordeaux, which is carrying out research into treatments for Type II diabetes and NASH (Non-Alcoholic-Steato-Hepatitis) has recently demonstrated success in recognised preclinical studies. Following an extensive review by ImmuPharma's Board of directors, it has been decided that Ureka, whilst having exciting and innovative technologies, is not part of the ongoing strategy of ImmuPharma, which is now fully focused on utilising its resources to develop late stage assets. As such, ImmuPharma, with its advisors, will now commence a process of considering all opportunities to divest Ureka. The intention is to allow ImmuPharma to divest Ureka, whilst still retaining an interest in any future commercial success." 2) Shareholder anticipation of more Lupuzor news. YoungHarry has stated "Mid November / early December, full analyses of PIII trial" and "The company will receive the full data from the PIII trial by the of end July / mid August, analysis will take a further two months and answers to key research issues will take a further two months after that. The key research findings will be published in peer reviewed journals." 3) Misplaced shareholder anticipation Take your pick. Read Full Thread Follow Reply
11/9/2018 18:44	obiterdicta: OT You haven't answered the points made. If you have any points to make I will consider them. You make generic points about valuation which are understood. See my response to UKDB below. UKDannyboy Thanks for the re-cap. I am not trying to convince anyone. If you look back at the thread it was Merlion who first raised cash assets to support his valuation. I did not raise it first but responded to Merlion's point. My point is in order to crystalise share price appreciation you need some inflection points, for example trial results. I can see no inflection points on the horizon for IMM but accept your point that Lupuzor may realise some value on conclusion of the MAP. The MAP does not conclude for another 2 years. My view is that Lupuzor realizing any value is a remote possibility and is some way off. So what inflection points do you see coming up for IMM to crsytalise share price appreciation? Do you accept my point that momentum is against IMM and management have lost credibility? OD Read Full Thread Follow Reply
10/9/2018 11:46	cockerspaniel: Sicilian: Yes,the die was cast long before Tim became involved. There remain some serious questions to be asked about the design of the phase III and the SPA, which was done by Cephalon (Immupharma only found out about it afterwards). Cephalon appear, with hindsigt, to have put as little resources into the development of Lupuzor as possible, and agreed the absolute bare minimum trial - i.e. one which would work only if Lupuzor performed exceptionlly well. Immupharma's management, however, seem to have represented things differently. That is hardly unusual in biotech, as founders and management are notoriously over-optimistic. So, what has Tim done:essentially he got the share price up, raised money from some private investors at a high price - the previous placings being done at a much lower level and were taken by serious investors (not mentioning any names). The unfortunate private investors may view the situation differently. Nothing that Tim or Dimitri do happens without the agreement of Robert Zimmer, who has been the driving force behind the company well before it came to the London market (sorry Richard and Dimitri), Now, what about Nobby? He has his own agenda - management change at Immupharma and a role for himself. That's not going to happen by silly postings on bulletin boards, but Nobby is nothing if not persistent. What about Immupharma? Hard to say, but looking at it from the perspective of a disappointed shareholder is not going to help. There might be some value for vultures or the cash might end up paying management's not ungenerous salaries for a while longer. Anyway, a lot has happened in 12 years and most of us (RIP Richard Warr) have lived to tell the tale. Read Full Thread Follow Reply
16/6/2018 21:46	spawny100: Never mind last couple of years petroc - IMM share price is back to 2003 levels. Anyone who sees value at these prices needs to seriously analyse why imo. Read Full Thread Follow Reply
01/5/2018 14:04	the_merlion: Mind you Ham, you have done better trolling then Growth and Nobby today. Fair play to you, I am sure you will make those thousands of pounds you lost with a entry at 150 back in the day. I guess you are a little scared to punt in, as you now only have 25% or the original pot left to work, but that is your own stupid fault LMFAO. hamhamham1 - 01 May 2018 - 13:49:36 - 30009 of 30012 IMMUPHARMA - IN FINAL PHASE 3 LUPUS TRIAL TARGETING BLOCKBUSTER ($1bn+) REVENUES - IMM Personally i trust Panmures ability to calculate an asset price over the posters on here. hamhamham1 - 01 May 2018 - 13:21:59 - 30000 of 30012 IMMUPHARMA - IN FINAL PHASE 3 LUPUS TRIAL TARGETING BLOCKBUSTER ($1bn+) REVENUES - IMM IMHO. If the company's share price was sub 40p before all the hype of the p3 started (end 2016) with still then with all that hope ahead. Then after the bad p3 readout then I reckon half that is a more than generous share price. hamhamham1 - 01 May 2018 - 12:20:34 - 29991 of 30012 IMMUPHARMA - IN FINAL PHASE 3 LUPUS TRIAL TARGETING BLOCKBUSTER ($1bn+) REVENUES - IMM My money is still on it hitting the Panmure Gordon target of 22p. Time will tell. hamhamham1 - 01 May 2018 - 12:03:20 - 29987 of 30012 IMMUPHARMA - IN FINAL PHASE 3 LUPUS TRIAL TARGETING BLOCKBUSTER ($1bn+) REVENUES - IMM If I bought shares here now, I would be buying on the hope that something comes over the horizon which is not currently scheduled to happen. Is that investing or gambling? hamhamham1 - 01 May 2018 - 11:28:27 - 29980 of 30012 IMMUPHARMA - IN FINAL PHASE 3 LUPUS TRIAL TARGETING BLOCKBUSTER ($1bn+) REVENUES - IMM What's the odds for hit 28p then drop? Read Full Thread Follow Reply
27/4/2018 08:26	growthinvestor2001: spmc - I remember you making wild claims about IMM share price too - look how that worked out. Just keep it to yourself....try and stop ramping / pumping for just one minute yeah? Read Full Thread Follow Reply
24/4/2018 10:30	hamhamham1: Merlion. Look, research companies are money pits they dilute shares and raise money all day long. They suck up money and nearly always end up with nothing of value to show for it. IMM share price went up based upon an immenant good p3 readout and thus real saleable asset value. It failed by over x5 the target level p value. The 22p is based upon that and not some pi investor hopes. Read Full Thread Follow Reply
19/4/2018 11:13	hamhamham1: Shares Logo Menu Shares News ImmuPharma crashes 85% as Phase III lupus trials flop 17 April 2018, 11:18 Shares in drug discovery company ImmuPharma (IMM:AIM) collapsed on Tuesday demonstrating just how risking early stage drug development really is. The company's lead drug Lupuzor failed to show meaningful statistical benefits over placebo in Phase III trials. Lupus is an autoimmune disease that affects millions, famously including American singer and actress Selena Gomez. This massive blow has wiped million of pounds off the company's market value as investors dump the stock. The share price has crashed 85% to 22.7p leaving the firm's market value at just £32m. The stunning scale of the sell-off is perhaps no surprise considering the £10m of fresh funding raised from investors as recently as January. That cash call was struck at 144p per share. In April 2017, we wrote about the blockbuster potential that had started to build among investors for Lupuzor. Those hopes look largely dashed now. ImmuPharma is far from alone at falling at clinical testing hurdles. Last year, Circassia (CIR) was forced to abandon its anti-allergy programme after its dust mite allergy study failed to show the treatment had a ‘significant effect’ compared to placebo. WHAT’S NEXT? ImmuPharma will undertake a review of the data and work with regulatory advisers to determine their next move. Talks are also ongoing with several large pharma companies. ‘Our initial reaction is to assume Lupuzor is no longer a meaningful candidate for marketing authorisation for the treatment of lupus and we now look to what would be a reasonable value for the business,’ comments Panmure Gordon’s Mike Mitchell. He argues for a £31m enterprise value, which strips out the anticipated £11m of net cash he estimates that the company will hold come year end on 31 December 2018. That implies a 22p share price. Deal now » Find out how to deal online from £1.50 Issue Date: 17 Apr 2018 Save Share Sign In or Subscribe to a Premium account to comment. Lisa-Marie Janes profile pic Lisa-Marie Janes Related news Weir makes splash with $1.29bn mining services deal, exposing itself even more to cyclical industry Market report: Cheers for Weir, downgrades for Debenhams Shares in cyber security and ID firm GB jump 12%, here’s why Hammerson listens to the market and walks away from Intu deal Rio Tinto defies major disruptions and avoids large downgrade to production guidance Shares in Animalcare slump on profit warning Dignity resurrected as deaths soar and more people opt for premium funerals than expected Asset manager Jupiter hit by clients withdrawing money and negative market conditions Market report: Hammerson up as M&A deal shelved Why asset manager Ashmore is in vogue today Shares Magazine Latest Issue Cover Latest Issue: 19 Apr 2018 Subscribe now @SharesMag @SharesMagDan: Today, 11:03 @wheeliedealer Hi WD - can you think of any stocks with a large net cash position relative to market cap? Thanks @SharesMagSteve: Today, 10:34 RT @SHARESmag: Weir makes splash with $1.29bn mining services deal, exposing itself even more to cyclical industry $WEIR hxxps://t.co/JMdr230; @SharesMagDan: Today, 10:17 RT @SHARESmag: Quality management is part of the success or failure of a company, which is why change at the top can often act as a catalys… < Previous Next > Terms And Conditions Investment Warning Privacy Disclaimers About Shares The Shares Team Contact Us Read Full Thread Follow Reply
18/4/2018 11:46	hamhamham1: ImmuPharma crashes 85% as Phase III lupus trials flop 17 April 2018, 11:18 Shares in drug discovery company ImmuPharma (IMM:AIM) collapsed on Tuesday demonstrating just how risking early stage drug development really is. The company's lead drug Lupuzor failed to show meaningful statistical benefits over placebo in Phase III trials. Lupus is an autoimmune disease that affects millions, famously including American singer and actress Selena Gomez. This massive blow has wiped million of pounds off the company's market value as investors dump the stock. The share price has crashed 85% to 22.7p leaving the firm's market value at just £32m. The stunning scale of the sell-off is perhaps no surprise considering the £10m of fresh funding raised from investors as recently as January. That cash call was struck at 144p per share. In April 2017, we wrote about the blockbuster potential that had started to build among investors for Lupuzor. Those hopes look largely dashed now. ImmuPharma is far from alone at falling at clinical testing hurdles. Last year, Circassia (CIR) was forced to abandon its anti-allergy programme after its dust mite allergy study failed to show the treatment had a ‘significant effect’ compared to placebo. WHAT’S NEXT? ImmuPharma will undertake a review of the data and work with regulatory advisers to determine their next move. Talks are also ongoing with several large pharma companies. ‘Our initial reaction is to assume Lupuzor is no longer a meaningful candidate for marketing authorisation for the treatment of lupus and we now look to what would be a reasonable value for the business,’ comments Panmure Gordon’s Mike Mitchell. He argues for a £31m enterprise value, which strips out the anticipated £11m of net cash he estimates that the company will hold come year end on 31 December 2018. That implies a 22p share price. Read Full Thread Follow Reply

Immupharma share price data is direct from the London Stock Exchange

Your Recent History

LSE

IMM

Immupharma

Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

ADVFN UK Investors Hub ADVFN Italy ADVFN Australia ADVFN Brazil

ADVFN Canada ADVFN Germany ADVFN Japan ADVFN Mexico

ADVFN France ADVFN US Finance Manila

P: V: D:20190522 22:39:49